Jyong Biotech (MENS) announced that it has achieved another milestone in the development of its plant-derived new drug MCS-8, PCP. The Company has completed the statistical analysis of the primary ...
Overview Leading endpoint security companies now rely heavily on AI and automation for faster threat detection.Cloud-based ...
Jaypirca is approved for the treatment of adults with relapsed or refractory CLL/SLL who were previously treated with a ...
Several ransomware groups have been spotted using a packer-as-a-service (PaaS) platform named Shanya to assist in EDR ...
Indianapolis: Eli Lilly and Company has announced results from the Phase 3 BRUIN CLL-314 clinical trial evaluating Jaypirca ...
Sensitive tests designed to detect very small numbers of remaining leukemia cells after treatment, known as measurable ...
Lilly reports Phase 3 CLL results showing Jaypirca matched and improved on Imbruvica across response rates and early progression trends, with safety consistent between treatments.
In addition to meeting the primary endpoint of non-inferiority for overall response rate (ORR) in the BRUIN CLL-314 study, pirtobrutinib achieved a numerically higher ORR of 87.0% compared to 78.5% ...
Cross-trial analysis supports plasma pTau as a potential early predictor of clinical benefit, reinforcing the biomarker-driven design of ProMIS’ ...
Kamada ends its Phase 3 inhaled AAT trial after a futility analysis but maintains 2025 guidance and forecasts double-digit growth in 2026.
9hon MSN
Continuous and fixed-duration treatments result in similar outcomes for chronic lymphocytic leukemia
According to a new trial, patients with chronic lymphocytic leukemia (CLL) show comparable outcomes whether they receive a ...
Today we are announcing expanded availability of AI, security, and management capabilities coming to Microsoft 365 offerings ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback